Colonoscopy proves cost-effective in young patients

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 11
Volume 17
Issue 11

Conducting colonoscopies for people in their mid 50s can save money, according to research presented at the 2008 American College of Gastroenterology meeting in Orlando, Fla. The savings averages $2 for every dollar spent, the study found.

Conducting colonoscopies for people in their mid 50s can save money, according to research presented at the 2008 American College of Gastroenterology meeting in Orlando, Fla. The savings averages $2 for every dollar spent, the study found.

Jianjun Li, MD, and colleagues at New York’s Maimonides Medical Center reported results of a study involving free screening colonoscopies for 248 consecutive patients (average age of 55). Nearly 45% had polyps. Follow-up testing demonstrated that fi ve individuals had early-stage colon cancer, and 22 had polyps larger than 1 cm.

The screening program cost $390,000. If colon cancer treatment had been delayed until the Medicare eligibility age of 65, the cost would have been nearly $1.3 million, Dr. Li said. If these patients had not been screened, their disease would have progressed undetected, said Judy Yee, MD, vice chair of radiology at the University of California, San Francisco. As people grow older, their risk of developing polyps increases, she said.

Recent Videos
Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.
2 experts are featured in this series.
1 expert is featured in this series.
2 experts are featured in this series.
Dordaviprone was recommended at a dose of 625 mg orally once weekly for adults, and the recommended dosage is based on body weight for pediatric patients.
Extended follow-up for individuals with H3 K27M-mutated diffuse midline glioma may help explain the duration of response across patient subgroups.
Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, described the excitement of seeing novel molecules like antibody drug conjugates become more prominent.